Clinical Report: EYP-1901 for Retinal Exudative Diseases
Overview
EYP-1901, a sustained-release intravitreal insert, shows results in phase 2 trials for wet AMD and DME, demonstrating noninferiority to aflibercept and extended treatment-free intervals. Ongoing phase 3 trials are evaluating its efficacy and safety.
Background
Retinal exudative diseases, such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME), pose significant challenges in clinical management, with many patients experiencing vision loss despite current anti-VEGF therapies. The need for more durable treatment options is critical due to the high burden of frequent injections and treatment discontinuation rates. EYP-1901 represents a novel approach, combining anti-VEGF and anti-inflammatory mechanisms.
Data Highlights
| Trial | Primary Endpoint | Results |
|---|---|---|
| DAVIO 2 | Noninferiority to aflibercept | Stable or improved vision in >85% of patients |
| VERONA | Extended time to first supplemental treatment | 70% supplement-free at Week 24 with EYP-1901 2.7 mg |
Key Findings
- EYP-1901 demonstrated noninferiority to aflibercept in the DAVIO 2 trial based on BCVA change.
- Over 85% of patients treated with EYP-1901 maintained stable or improved vision six months post-treatment.
- In the VERONA trial, both EYP-1901 doses achieved longer time to first supplemental treatment compared to aflibercept.
- Mean BCVA improvements were +6.9, +7.1, and +7.3 letters for EYP-1901 1.3 mg, 2.7 mg, and aflibercept 2 mg, respectively.
Clinical Implications
The findings from the DAVIO 2 and VERONA trials suggest that EYP-1901 may reduce the treatment burden associated with current therapies while maintaining vision outcomes. Ongoing phase 3 trials will provide further insights into its long-term efficacy and safety in clinical practice.
Conclusion
EYP-1901 shows promise as a durable treatment option for retinal exudative diseases, with ongoing trials expected to clarify its role in clinical management.
Related Resources & Content
- EyePoint Pharmaceuticals, New Retinal Physician, 2024 -- EyePoint Presents EYP-1901 Data for Wet AMD
- Ashkan M. Abbey, Retinal Physician, 2026 -- EYP-1901 Approaches a Pivotal Fall
- Jim Gallagher, Retinal Physician, 2025 -- EYP-1901 Shows 9-Month Disease Control in NPDR Patients
- The Ophthalmologist, 2026 -- EYP-1901 in Wet AMD and DME: Insights from the Phase 2 DAVIO 2 and VERONA Trials
- American Diabetes Association, Diabetes Care, 2026 -- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026
- PMC, 2025 -- Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
- Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials - PMC
- Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular Degeneration - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
